Sökning: onr:"swepub:oai:gup.ub.gu.se/326172" >
The amyloid-beta pa...
The amyloid-beta pathway in Alzheimer's disease: a plain language summary
-
- Hampel, H. (författare)
- Eisai Inc, Alzheimers Dis & Brain Hlth, Nutley, NJ 07110 USA.
-
- Hu, Y. (författare)
- Eisai Inc, Alzheimers Dis & Brain Hlth, Nutley, NJ 07110 USA.
-
- Hardy, J. (författare)
- UCL, UK Dementia Res Inst, London, England.;UCL, UCL Inst Neurol, Dept Neurodegenerat Dis, London, England.
-
visa fler...
-
- Blennow, Kaj, 1958 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry,Sahlgrens Univ Hosp, Clin Neurochem Lab, Mölndal, Sweden.;Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Sahlgrenska Acad, Mölndal, Sweden.
-
- Chen, C. S. P. (författare)
- Natl Univ Singapore, Memory Aging & Cognit Ctr, Yong Loo Lin Sch Med, Dept Pharmacol & Psychol Med, Singapore, Singapore.
-
- Perry, G. (författare)
- Univ Texas San Antonio, Dept Biol & Neurosci Inst, San Antonio, TX USA.
-
- Kim, S. H. (författare)
- Hanyang Univ, Coll Med, Dept Neurol, Seoul, South Korea.;Hanyang Univ Hosp, Cell Therapy Ctr, Seoul, South Korea.
-
- Lannfelt, Lars (författare)
- Uppsala universitet,Geriatrik,BioArct AB, Stockholm, Sweden.,Univ Nevada Las Vegas, Chambers Grundy Ctr Transformat Neurosci, Sch Integrated Hlth Sci, Dept Brain Hlth, Las Vegas, NV USA.
-
- Aisen, P. (författare)
- Univ Southern Calif, Alzheimers Therapeut Res Inst, San Diego, CA USA.
-
- Vendruscolo, M. (författare)
- Univ Cambridge, Ctr Misfolding Dis, Dept Chem, Cambridge, England.
-
- Iwatsubo, T. (författare)
- Univ Tokyo, Grad Sch Med, Dept Neuropathol, Tokyo, Japan.
-
- Masters, C. L. (författare)
- Florey Inst, Parkville, Vic, Australia.;Univ Melbourne, Parkville, Vic, Australia.
-
- Cho, M. (författare)
- Eisai Inc, Alzheimers Dis & Brain Hlth, Nutley, NJ 07110 USA.
-
Lannfelt, L. (författare)
-
Cummings, J. L. (författare)
-
- Vergallo, A. (författare)
- Eisai Inc, Alzheimers Dis & Brain Hlth, Nutley, NJ 07110 USA.
-
visa färre...
-
Eisai Inc, Alzheimers Dis & Brain Hlth, Nutley, NJ 07110 USA UCL, UK Dementia Res Inst, London, England.;UCL, UCL Inst Neurol, Dept Neurodegenerat Dis, London, England. (creator_code:org_t)
- 2023-03-30
- 2023
- Engelska.
-
Ingår i: Neurodegenerative Disease Management. - : Future Medicine Ltd. - 1758-2024 .- 1758-2032. ; 13:3, s. 141-9
- Relaterad länk:
-
https://doi.org/10.2...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://gup.ub.gu.se...
-
https://doi.org/10.2...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- What is this summary about? This plain language summary of an article published in Molecular Psychiatry, reviews the evidence supporting the role of the amyloid-b (Ab) pathway and its dysregulation in Alzheimer's disease (AD), and highlights the rationale for drugs targeting the A beta pathway in the early stages of the disease. Why is this important? A beta is a protein fragment (or peptide) that exists in several forms distinguished by their size, shape/structure, degree of solubility and disease relevance. The accumulation of A beta plaques is a hallmark of AD. However, smaller, soluble aggregates of A beta - including Ab protofibrils - also play a role in the disease. Because A beta-related disease mechanisms are complex, the diagnosis, treatment and management of AD should be reflective of and guided by up-to-date scientific knowledge and research findings in this area. This article describes the A beta protein and its role in AD, summarizing the evidence showing that altered A beta clearance from the brain may lead to the imbalance, toxic buildup and misfolding of the protein - triggering a cascade of cellular, molecular and systematic events that ultimately lead to AD. What are the key takeaways? The physiological balance of brain A beta levels in the context of AD is complex. Despite many unanswered questions, mounting evidence indicates that A beta has a central role in driving AD progression. A better understanding of the A beta pathway biology will help identify the best therapeutic targets for AD and inform treatment approaches.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Nyckelord
- Alzheimer's disease
- amyloid beta
- A beta plaques
- biomarkers
- dementia
- protofibrils
- tau
- Alzheimer's disease
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hampel, H.
-
Hu, Y.
-
Hardy, J.
-
Blennow, Kaj, 19 ...
-
Chen, C. S. P.
-
Perry, G.
-
visa fler...
-
Kim, S. H.
-
Lannfelt, Lars
-
Aisen, P.
-
Vendruscolo, M.
-
Iwatsubo, T.
-
Masters, C. L.
-
Cho, M.
-
Lannfelt, L.
-
Cummings, J. L.
-
Vergallo, A.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Neurovetenskaper
- Artiklar i publikationen
-
Neurodegenerativ ...
- Av lärosätet
-
Göteborgs universitet
-
Uppsala universitet